YOLFTbeta
BORA PHARMACEUTICALS LTD

BORA PHARMACEUTICALS LTD

6472 · TW · Healthcare / Drug Manufacturers - Specialty & Generic

402.00TWD+1.00 (+0.25%)

Price History

Full chart

Market Stats

Previous Close401.00
Open402.50
Day Range398.00 – 416.00
52-Week Range321.89 – 674.95
Volume763.23K
Market Cap53.64B
P/E (TTM)32.90
Forward P/E0.00
EPS12.78
Dividend Yield2.38%
Beta0.46
50-Day Avg418.71
200-Day Avg443.65

About

Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services for the development of pharmaceutical products. In addition, it provides Western pharmaceuticals, including central nervous system medications, antibiotics, and gastrointestinal medications; and nutritional and vitamin supplements, physical recovery, and health care products. The company sells its products directly to clinics, pharmacies, pharmacy chains, and drug stores, as well as through distributors to medical centers, corporate and public hospitals, and regional and district hospitals. Bora Pharmaceuticals Co., LTD. was incorporated in 2007 and is based in Taipei City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Pao-Shi Sheng
  • Employees0
  • HeadquartersNo. 2, Ruiguang Road, Taipei, Taiwan, 114, Taiwan
  • Websitehttps://www.bora-corp.com

Leadership

  • Mr. Pao-Shi ShengChairman, GM & CEO
  • Ms. Alice WangCFO of HQ & APAC
  • Xiaoting ChenAccounting Supervisor
  • Ms. Ellen ChenCorporate Human Resource Director
  • Tom ChangSenior Vice President of Taiwan Site Operations
  • Xiu-Rong ZhangDeputy General Manager
  • Zhen-Tang ZhangDeputy General Manager
  • Ms. Nadiya ChenSenior Manager of IR/PR

Financials

Income Statement

Currency: TWD2019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Revenue1.53B1.80B4.90B10.49B14.20B19.25B19.01B
Growth (%)-+17.68%+172.28%+114.18%+35.31%+35.53%-1.21%
Cost of Revenue886.18M1.10B3.23B7.58B7.21B11.54B11.35B
Gross Profit643.03M703.88M1.67B2.91B6.99B7.71B7.66B
Gross Margin42.05%39.11%34.12%27.76%49.23%40.06%40.29%
Operating Expense298.19M474.37M594.19M964.05M1.74B4.33B4.37B
Operating Income344.85M229.51M1.08B1.95B5.25B3.38B3.29B
Operating Margin22.55%12.75%21.99%18.57%36.97%17.58%17.32%
EBITDA452.04M367.10M1.29B2.27B5.73B6.46B4.23B
EBITDA Margin29.56%20.40%26.28%21.67%40.38%33.57%22.25%
Net Income305.03M578.43M749.74M1.39B3.03B3.94B2.98B
Net Income Margin19.95%32.14%15.30%13.26%21.34%20.47%15.68%
R&D39.65M36.65M41.27M129.08M298.16M694.49M672.21M
R&D as % of Total Revenue2.59%2.04%0.84%1.23%2.10%3.61%3.54%
Interest Expense14.54M21.97M53.62M108.73M171.24M479.72M484.62M
Interest Expense % of Total Revenue0.95%1.22%1.09%1.04%1.21%2.49%2.55%

Balance Sheet

Currency: TWD2019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Assets3.38B7.00B7.37B22.76B25.05B45.60B44.71B
Total Liabilities1.73B4.54B4.22B17.62B13.29B30.59B27.24B
Total Equity1.65B2.46B3.15B4.53B9.08B12.87B15.38B
Cash452.68M669.99M910.75M3.28B3.05B5.83B5.12B
Total Debt1.41B2.88B2.23B7.60B5.01B18.98B18.23B
Net Debt956.64M2.21B1.32B4.32B1.96B13.15B13.11B

Cash Flow

Currency: TWD2019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Operating Cash Flow231.77M177.79M1.24B2.01B4.61B980.81M4.24B
Investing Cash Flow-827.49M-1.54B-225.85M-4.28B-2.46B-10.68B-3.45B
Financing Cash Flow551.01M1.58B-741.40M4.59B-2.44B12.07B-1.04B
Capital Expenditure697.33M152.09M363.58M200.22M1.43B687.05M928.67M
Free Cash Flow-465.56M25.70M873.05M1.81B3.18B293.76M3.31B
Dividends Paid88.49M83.25M109.77M238.80M619.13M1.23B1.45B
FCF to OCF-200.87%14.45%70.60%90.04%69.00%29.95%78.11%
Dividend Paid to FCF-19.01%323.97%12.57%13.19%19.45%419.67%43.73%

Earnings

Report DateNov 13, 2019May 13, 2020Aug 13, 2020Nov 12, 2020May 13, 2021Aug 11, 2021Nov 11, 2021May 9, 2022Aug 11, 2022Nov 14, 2022Mar 20, 2023Aug 14, 2023Nov 9, 2023Mar 7, 2024May 14, 2024Aug 13, 2024Nov 13, 2024Mar 5, 2025May 14, 2025Aug 8, 2025Nov 13, 2025Mar 11, 2026Mar 31, 2026Aug 13, 2026
EPS Estimate0.870.700.560.821.791.961.681.391.482.546.957.775.545.456.368.386.879.6121.316.456.469.840.725.73
EPS Actual0.890.390.370.622.861.171.181.522.054.843.347.346.075.087.079.3811.795.8210.625.834.992.780.204.24
Surprise2.30%-44.29%-33.93%-24.39%59.78%-40.31%-29.76%9.35%38.51%90.55%-51.94%-5.53%9.57%-6.79%11.16%11.93%71.62%-39.44%-50.16%-9.61%-22.76%-71.75%-72.22%-26.00%
Timing-After-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-market

Key Statistics & Ratios

Market Cap53.64B
Enterprise Value68.95B
Trailing P/E32.90
Forward P/E0.00
Price / Sales2.74
Price / Book3.68
EPS12.78
Book Value118.83
Revenue (TTM)19.56B
Gross Profit (TTM)7.82B
EBITDA3.97B
Profit Margin7.91%
Operating Margin16.75%
Return on Equity12.05%
Return on Assets4.01%
Shares Outstanding127.57M
Shares Float74.29M
Beta0.46
Dividend Yield2.38%
Dividend Rate10.00
Payout Ratio81.90%

Dividends

20261×
10.00Jul 31, 2026
20251×
11.67Jun 20, 2025
20241×
10.00Aug 12, 2024
20231×
5.13Jul 6, 2023
20221×
2.04Jul 7, 2022
20211×
1.17Sep 7, 2021
20201×
0.72Jul 6, 2020
20191×
1.07Jul 31, 2019
20181×
0.14Jul 16, 2018
20171×
0.22Jul 25, 2017
20161×
0.16Jul 18, 2016
20151×
0.13Sep 3, 2015

Stock Splits

  • Aug 4, 20251199.7915:1000
  • Aug 10, 20231298.9034:1000
  • Aug 30, 20221100.4294:1000
  • Sep 7, 20211246.502:1000
  • Nov 9, 20201300:1000
  • Jul 31, 20191299.929:1000
  • Jul 18, 20161040.132:1000